Partner Headlines - AMGN

  1. AMGEN

    IBD
  2. #PreMarket Primer: Tuesday, November 25: Violent Protests In ...

    Benzinga
  3. Dividend Aristocrats In Focus Part 45: AbbVie

    GuruFocus
  4. Amgen Announces Termination Of All Amgen-Sponsored Clinical Studies ...

    Benzinga
  5. #PreMarket Primer: Wednesday, November 19: Burst Of Cold Creates ...

    Benzinga
  6. Merck Drug Works: Vytorin Study Proves Successful

    IBD
  7. Events for the Week of Nov. 17-21, 2014

    Benzinga
  8. Amgen Shares Consolidating Ahead Of More Gains?

    Benzinga
  9. UPDATE: Deutsche Bank Reiterates On Amgen On Potential Of New ...

    Benzinga
  10. Amgen And AstraZeneca Announce Positive Results From Second Pivotal ...

    Benzinga
  11. Big Cap 20 Stuffed With Medical Names

    IBD
  12. Markets Mostly Lower As Americans Head To Vote, Oil Continues ...

    Benzinga
  13. AbbVie Beats Q3 Earnings Estimates, Raises Guidance

    IBD
  14. Ebola Vaccine Contenders

    Benzinga
  15. Stocks Trim Losses After Fed Report; Solarwinds Soars

    IBD
  16. UPDATE: Nomura Upgrades Amgen

    Benzinga
  17. Amgen resists pressure to split

    IBD
  18. Amgen: Stronger Drug Portfolio with Acquisition

    GuruFocus
  19. Amgen Refuses To Split, But Plans Hearten Investors

    IBD
  20. Amgen At All-Time High, Deutsche Bank Ups Price Target

    Benzinga
  21. Stocks Extend Gains As Alibaba, Tesla Rally

    IBD
  22. Stocks Launch In Climbing Mood; Amgen, Spirit Airlines Climbing

    IBD
  23. Amgen Rallies 3% After Announcing Growth And Capital Plans

    Benzinga
  24. Four Biotechs Lead Health Care Stocks In Big Cap 20

    IBD
  25. Amgen Q3 Earnings Beat Estimates; Guidance Mixed

    IBD
  26. Amgen Earnings Clear Views

    IBD
  27. Amgen Beats Q3 Earnings Estimates

    Benzinga
  28. Twitter Off, Amgen, Buffalo Wild Wings Up After Hours

    IBD
  29. Dow, Nasdaq Battle Near Flat Line; Energy Weighs On S&P 500

    IBD
  30. #PreMarket Primer: Monday, October 27: ECB Stress Tests In-Line ...

    Benzinga
  31. Earnings Scheduled For October 27, 2014

    Benzinga
  32. Keep an Eye on These 7 Stocks for October 27, 2014

    Benzinga
  33. Stocks Put End To Four-Week Slide

    IBD
  34. Fast Money Picks For October 23

    Benzinga
  35. Drug ETFs Attractive Buys On Pullback

    Benzinga
  36. Biotechs Show Fed Chief's Not Much Of A Stock Analyst

    IBD
  37. Daniel Loeb Comments on Amgen Inc

    GuruFocus
  38. Third Point Q3 2014 Investor Letter

    GuruFocus
  39. Markets In Rally Mode: S&P 500 And Nasdaq Surge As Dow Lags

    Benzinga
  40. Third Point's Notable Additions And Exit: Alibaba, eBay, Sony

    Benzinga
  41. Stocks To Watch For October 20, 2014

    Benzinga
  42. Celgene, Alexion Among 4 IBD 50 Medical s To Report

    IBD
  43. Regeneron's Eylea Tops Rivals

    IBD
  44. Amgen Announces Appointment Of R. Sanders Williams To Board Of ...

    Benzinga
  45. Regeneron Eye Drug Beats Rivals While Amgen Sues

    IBD
  46. Amgen Files Lawsuit Against Sanofi And Regeneron For Patent Infringement

    Benzinga
  47. Most Top Industry Groups Fall Harder Than Market

    IBD
  48. UPDATE: Amgen's BiTE Received FDA Priority Review Designation

    Benzinga
  49. Illumina Pads Gene Sequencing Lead With Pharma Deals

    IBD
  50. Some Old Stocks Still Have Young Legs

    IBD
  51. Amgen, Inc. Showing Strong Performance Despite Low Beta

    Benzinga
  52. Acorda To Buy Civitas, Gains Parkinson's Disease Drug

    IBD
  53. Most Big Cap 20 Stocks Near Entries, But Risks Exist

    IBD
  54. These 3 Biotech Stocks Just Hit New Highs

    Benzinga
  55. Amgen Submits Biologics License Application For Investigational ...

    Benzinga
  56. Amgen: Stronger Drug Portfolio with Acquisition

    GuruFocus
  57. Insider Buys at Halozyme Look to Improve Stock Outlook

    GuruFocus
  58. Amgen, Inc. Poised To Break Higher

    Benzinga
  59. UPDATE: Morgan Stanley Reiterates On Amgen, Inc. As Brodalumab ...

    Benzinga
  60. UPDATE: Morgan Stanley Reiterates On Amgen, Inc. Following Healthcare ...

    Benzinga
  61. Amgen, Inc. Showing More Upside Potential

    Benzinga
  62. Why Gilead Sciences, Inc. Is A Top Mutual Fund Holding

    Benzinga
  63. Novartis, Regeneron Cardio Results Pump Up Wall St.

    IBD
  64. Novartis, Regeneron Hit New Highs On Cardio Drugs

    IBD
  65. Amgen edges up on trial results

    IBD
  66. Stocks Hitting 52-Week Highs

    Benzinga
  67. Biotech ETFs Hitting New Highs On Takeover News (FBT, PBE, ITMN)

    Benzinga
  68. After Reaching All-Time Highs, How Can Gilead Sciences Continue ...

    GuruFocus
  69. HCP Boosts Of 29 Years Of Dividend Increases

    IBD
  70. The Tech Industry is Vanishing Before Our Eyes

    FoxBusiness
  71. Stocks End With Small Gains; Amgen Shrugs Off Drug Data

    IBD
  72. AMGEN

    IBD
  73. Top 4 Stocks In The Biotechnology Industry With The Highest Revenue

    Benzinga
  74. 4 Top-Rated Drugmakers Beat Q2 Earnings Estimates

    IBD
  75. Cancer 'Cocktail' Passes Test

    IBD
  76. Nasdaq Leads In Quiet Session; Priceline Nears Buy Point

    IBD
  77. Amgen Cancer Drug Kyprolis Succeeds In Trial

    IBD
  78. Morning Market Movers

    Benzinga
  79. Benzinga's Top #PreMarket Gainers

    Benzinga
  80. UPDATE: Amgen Announces Phase 3 ASPIRE Trial of Kyprolis Met ...

    Benzinga
  81. Stocks Mixed Despite Better-Than-Expected GDP

    Benzinga
  82. Amgen Price Target Raised by Various Analysts

    Benzinga
  83. Amgen Restructuring Plan, Q2 Earnings Send Stock Up

    IBD
  84. Quarterly “Beats”: Bah, Here Are Real Growers

    YCharts
  85. Amgen To Slash Workforce

    IBD
  86. Indexes End Lower As Russia Sanctions Hit Stocks

    IBD
  87. Stock Futures Show Some Muscle; Merck, Cognex Rising

    IBD
  88. Earnings Scheduled For July 29, 2014

    Benzinga
  89. Top 5 Earnings Reports To Watch After The Close Tue.

    IBD
  90. Pfizer, Merck, Amgen Near Q2 Earnings Reports

    IBD
  91. Benzinga Weekly Preview: FOMC In Focus, As Earnings Season Progresses

    Benzinga
  92. US Stock Futures Drop Ahead Of Durable Goods Orders Data

    Benzinga
  93. Biotech Enters Reporting Season With Large Caps Central To Sector ...

    Benzinga
  94. UPDATE: Amgen Announces Positive Phase 3 Results For AMG 416 ...

    Benzinga
  95. Yellen Swats Down Biotech, Social Media Stocks

    FoxBusiness
  96. Morgan Stanley Issues 2015 'Vintage Values' Stock List

    Benzinga
  97. Celgene Drug Otezla Fails Trial, But Street Sanguine

    IBD
  98. Alexion Pharma Looks To Life Beyond Its Blockbuster

    IBD
  99. Bind Therapeutics

    IBD
  100. Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector

    Benzinga
Trading Center